Benjamin Graham fit · Defensive deep-value investing
Is Corcept Therapeutics Incorporated (CORT) a Benjamin Graham Stock?
Meets 4/7 Graham criteria - classic deep-value candidate.
84/100
CMixed signals
4/7 criteria passed
+4 sector-quality lift. Top-quintile within its sector on 2 of 5 quality metrics. Raw pillar score 80 → lifted to 84 before grade derivation.
Capped from A to C. Net debt over 8x EBITDA - even Graham's margin of safety can't survive this What are deal-breaker caps?
Benjamin Graham's Criteria, Applied to CORT
P/E ≤ 15
key122.0x
P/B ≤ 1.5
key9.2x
Current ratio ≥ 2
2.9x
Debt / Equity ≤ 1
0.0x
5y profitable
keyYes
Earnings yield ≥ 7%
0.8%
Revenue growing
20.1%
How CORT Scores on Other Strategies
Live Financial Snapshot
Market cap
$9.63B
P/E (TTM)
122.0x
ROIC (TTM)
-1.23%
Gross margin
98.25%
Other Benjamin Graham fit reports
Frequently Asked Questions
What is CORT's Benjamin Graham fit score?
CORT scores 84/100 on our Benjamin Graham fit engine - grade C. Meets 4/7 Graham criteria - classic deep-value candidate.
Does Benjamin Graham actually own CORT?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends CORT.
How often is this score updated?
CORT's Benjamin Graham fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Key terms in this analysis
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Benjamin Graham personally owns or recommends CORT.